REDWOOD CITY, Calif.,
April 30, 2018 /PRNewswire/ -- AcelRx
Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical
company focused on the development and commercialization of
innovative therapies for use in medically supervised settings,
today announced the publication of two studies commissioned by
AcelRx analyzing errors involved with intravenous (IV)
patient-controlled analgesia (PCA) systems in two peer-reviewed
journals, Therapeutic Advances in Drug Safety and Expert
Opinion on Drug Safety. These studies analyzed IV-PCA
medication errors which were submitted to the MEDMARX database, and
the nature, magnitude, and reporting compliance of device-related
events for IV-PCA in the U.S. Food and Drug Administration (FDA)
Manufacturer and User Facility Device Experience (MAUDE) database.
The studies conclude that IV-PCA is associated with common and
preventable medication errors that jeopardize patient safety. The
studies suggest the need for new and improved PCA systems that
reduce human error, as patient-controlled systems remain an
important component of acute pain care for hospitalized
patients.
"The use of existing IV patient-controlled analgesia systems
often results in adverse drug- and device-related events which can
cause serious complications for patients," commented Dr.
Pamela Palmer, AcelRx Chief Medical
Officer. "Many of these complications are preventable and
safety could be greatly improved through the use of a less complex,
non-invasive PCA system, such as AcelRx's sublingual PCA system
Zalviso®."
Details on the publications:
Mohanty M, Lawal O, Skeer
M, Lanier R, Erpelding N, Katz N. Medication Errors Involving
Intravenous Patient-Controlled Analgesia: Results from the
2005–2015 MEDMARX Database. Therapeutic Advances in Drug
Safety. 2018 April.
Lawal O, Mohanty M, Elder H, Skeer M, Erpelding N, Lanier R,
Katz N. The nature, magnitude, and reporting compliance of
device-related events for intravenous patient-controlled analgesia
in the FDA Manufacturer and User Facility Device Experience (MAUDE)
database. Expert Opinion on Drug Safety. 2018 February.
About the Journals:
Therapeutic Advances in Drug
Safety delivers the highest quality peer-reviewed articles,
reviews, and scholarly comment on pioneering efforts and innovative
studies pertaining to the safe use of drugs in patients. The
journal has a strong clinical and pharmacological focus and is
aimed at clinicians and researchers in drug safety, providing a
forum in print and online for publishing the highest quality
articles in this area.
Expert Opinion on Drug Safety is a MEDLINE-indexed,
peer-reviewed, international journal publishing review articles on
all aspects of drug safety and original papers on the clinical
implications of drug treatment safety issues, providing expert
opinion on the scope for future development.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for use in medically supervised settings. AcelRx's
proprietary, non-invasive sublingual formulation technology
delivers sufentanil with consistent pharmacokinetic profiles. The
company has two product candidates including DSUVIA™ (sufentanil
sublingual tablet, 30 mcg), known as DZUVEO outside the United States, with a proposed indication
for the treatment of moderate-to-severe acute pain in medically
supervised settings, and Zalviso® (sufentanil sublingual tablet
system, 15 mcg) being developed as an innovatively designed
patient-controlled analgesia (PCA) system for reduction of
moderate-to-severe acute pain in hospitalized patients.
For additional information about AcelRx's clinical programs,
please visit www.acelrx.com.
View original content with
multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-reports-publication-analyzing-errors-associated-with-existing-iv-patient-controlled-analgesia-systems-300638490.html
SOURCE AcelRx Pharmaceuticals, Inc.